Developing extracellular vesicle therapeutics for cardiovascular inflammation

Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide?

Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for inflammatory cardiovascular disease.

Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of cardiovascular disease, improve patient outcomes, and prolong healthy lifespan.

This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat cardiovascular disease.

LONG-TERM GOALS

1. Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat cardiovascular inflammation.
2.  Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.
3. Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.